Hair-loss treatment now arrives in nearly identical bottles with very different active ingredients. One may contain minoxidil. Another may combine minoxidil and finasteride. A third may add tretinoin, ketoconazole, or other ingredients. The convenience is real. So is the need to read past the front label.

The word topical describes where a product is applied. It does not guarantee that the drug stays in the scalp, that side effects are only local, or that the formulation is FDA-approved.

A spray is a delivery route, not a safety category.

First confirm the diagnosis

Androgenetic alopecia, commonly called male pattern hair loss, often progresses gradually in a recognizable pattern. Sudden shedding, patchy loss, scalp inflammation, scarring, medication changes, illness, or nutritional problems can point elsewhere. The FDA labeling for topical minoxidil tells users not to self-treat when the reason for hair loss is unknown or when loss is sudden or patchy.

That distinction matters because a product can be effective for one cause and irrelevant for another. Baseline photographs taken in consistent lighting and position are more useful than memory. A clinician can also examine the scalp, review the timeline, and decide whether laboratory work or a different evaluation is warranted.

Minoxidil

Topical minoxidil is an FDA-approved over-the-counter treatment for pattern hair loss in defined populations and scalp regions. Product labels set the concentration, frequency, intended user, application area, warnings, and expected timeline. More product does not mean faster growth.

Consistency is the difficult part. Benefits take months, and continued use is generally needed to maintain them. Local irritation can occur. Systemic symptoms such as chest pain, rapid heartbeat, faintness, swelling, or unexplained weight gain require stopping and seeking medical advice under the label instructions.

Finasteride

Oral finasteride 1 mg is FDA-approved for male pattern hair loss in men. It reduces conversion of testosterone to dihydrotestosterone, or DHT. Its approved label includes sexual adverse reactions and other warnings that should be part of informed consent.

Topical finasteride is different. A phase III randomized trial of a specific topical spray formulation reported improved hair counts compared with placebo and lower systemic exposure than oral finasteride. That is evidence for the studied formulation under the studied conditions. It does not convert every compounded spray into the same product.

In April 2025, the FDA warned about potential risks associated with compounded topical finasteride. The agency stated that there is no FDA-approved topical finasteride product and that systemic absorption is expected. It also described adverse-event reports and risk of transfer to others, including people who are or may be pregnant.

Combination sprays

A minoxidil-finasteride spray combines two mechanisms, but it also makes attribution harder. If scalp irritation, sexual symptoms, dizziness, or another problem appears, two active drugs changed at once. Additional ingredients can further complicate the picture.

Before using a compounded combination, ask for:

  • Every active ingredient and its concentration.
  • The prescribed application amount and frequency.
  • The pharmacy that compounds it and the beyond-use date.
  • Expected local and systemic adverse effects.
  • Transfer precautions for partners, children, and pets.
  • The outcome, review date, and stop conditions.

Measure the result that matters

Hair protocols are slow experiments. Use standardized photographs at baseline and at defined intervals. Record missed applications and side effects. Decide in advance how many months will pass before judging the result. A brief shed, a missed week, or a different haircut can distort a casual comparison.

Public educators such as Derek of More Plates More Dates have helped make DHT, finasteride, and combination protocols part of mainstream men's health discussion. That context can help identify the questions. Product-specific evidence, regulatory status, and individual clinical judgment still determine the answer.

Hair loss sits at the intersection of Body and Vitality. Appearance matters, but so do sexual health, fertility plans, cardiovascular symptoms, and the burden of indefinite treatment. Read the formula, not the marketing name.